Press Releases
 
Spinal Muscular Atrophy Market : Industry Perspective And Comprehensive Analysis 2023

, 21 April 2017 -- The number of people affected with spinal muscular atrophy is increasing globally. As stated in a publication by CureSMA, at least one in fifty people carry the defective spinal muscular atrophy gene.

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.

Obtain Report Details @ http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html

In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039. The report also mentions some of the potential preclinical candidates in the spinal muscular atrophy pipeline. The pipeline analysis of spinal muscular atrophy (SMA) market report provides overview of the clinical trials, and its current status for each drug candidate for treatment of spinal muscular atrophy. Details on mergers, acquisitions, licensing agreements, and other collaborative agreements, updated on regulatory policies, and expected study completion are also mentioned in the report. Market estimation and forecast for phase 3 drugs for treatment of spinal muscular atrophy has been provided from the expected year of drug approval, till 2023 (in USD Million) for the United States.

Pipeline analysis of late stage (phase 3) drugs for treatment of spinal muscular atrophy adopts patient based approach, in which actual patient population that can be targeted by the new drug is considered to arrive at probable sales of the drug in the launch year. Forecast model considers various macro- as well as micro-economic factors such as drug efficiency, side effects, prevalence and incidence rate, impact of regulatory policies, impact of competitor drugs and generic competition (if applicable) and pipeline status. The report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7187

Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. These include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Ionis Pharmaceuticals, Inc. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

# # #


Media Contacts:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:
Website: http://www.transparencymarketresearch.com/

Submitted by Sandy Researcher, Transparency Market Research on Friday, 21 April 2017 at 7:45 PM
Category: Health Care & Medical
 
Related News

Obtain 2007 runescape gold with Up To 10% Bonus on Rsorder for Fossil Island Until May 10
Monday, 24 Apr 2017

Emergency dental care in Los Angeles
Monday, 24 Apr 2017

Get The Best Cincinnati SEO & Digital Marketing Services To Boost Your Online Business
Sunday, 23 Apr 2017

Qherb Launches White Peony Extract For People to Prevent Cardiovascular Problems & Boost Immunity
Saturday, 22 Apr 2017

RxPhoto’s mobile medical photography platform impresses healthcare providers with V3 release
Saturday, 22 Apr 2017

Related Events

World Congress on Maternal Fetal Neonatal Medicine
Sunday, 23 Apr 2017

85th EAS Congress - European Atherosclerosis Society
Sunday, 23 Apr 2017

Radiology in Venice
Monday, 24 Apr 2017

6th Digital Marketing for Medical Devices West
Monday, 24 Apr 2017

Gene Therapy for Rare Disorders 2017
Monday, 24 Apr 2017

Latest News

Obtain 2007 runescape gold with Up To 10% Bonus on Rsorder for Fossil Island Until May 10
Monday, 24 Apr 2017

Gain runescape 3 gold with Up To 10% Bonus on Rsorder for Free XP Until May 10
Monday, 24 Apr 2017

TEPCO: Free Electrons Announces Cohort of 12 Energy Startups
Monday, 24 Apr 2017

www.unitedkingdominbusiness.co.uk offers great opportunities for free advertising strategies
Monday, 24 Apr 2017

Emergency dental care in Los Angeles
Monday, 24 Apr 2017

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2017
Today is Monday, 24 April 2017

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • How to backup files in your laptop
  • World Congress on Maternal Fetal Neonatal Medicine
  • 85th EAS Congress - European Atherosclerosis Society
  • Leveraging Customer Contact as a Strategic Asset: Customer Contact, East
  • Radiology in Venice

  • Latest Jobs
  • London Investment Property
  • We Are Hiring A Content Manager!